A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme in China
Phase: PHASE3
Conditions: Infertility, Female
Sponsor: Ferring Pharmaceuticals

 
Sponsor name 
Ferring Pharmaceuticals A/S 
NCT Number 
NCT06173869 
Sponsor Trial ID 
000413 
Official Title of Study 
A Randomised Trial Comparing the Ovarian Response of a Starting 
Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a 
Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in 
Conventional Regimens in China (COCO) 
Document Date 
19 October 2023 
 

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________

________________